- Home
- CNA vs BMRN Comparison
CNA vs BMRN Comparison
Compare CNA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNA
- BMRN
- Stock Information
- Founded
- CNA 1853
- BMRN 1996
- Country
- CNA United States
- BMRN United States
- Employees
- CNA N/A
- BMRN N/A
- Industry
- CNA Property-Casualty Insurers
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CNA Finance
- BMRN Health Care
- Exchange
- CNA Nasdaq
- BMRN Nasdaq
- Market Cap
- CNA 13.2B
- BMRN 12.1B
- IPO Year
- CNA N/A
- BMRN 1999
- Fundamental
- Price
- CNA $45.26
- BMRN $55.00
- Analyst Decision
- CNA Sell
- BMRN Buy
- Analyst Count
- CNA 2
- BMRN 22
- Target Price
- CNA $50.50
- BMRN $93.43
- AVG Volume (30 Days)
- CNA 363.8K
- BMRN 2.2M
- Earning Date
- CNA 07-28-2025
- BMRN 08-04-2025
- Dividend Yield
- CNA 8.42%
- BMRN N/A
- EPS Growth
- CNA N/A
- BMRN 152.82
- EPS
- CNA 3.28
- BMRN 2.71
- Revenue
- CNA $14,453,000,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- CNA $7.41
- BMRN $12.23
- Revenue Next Year
- CNA $6.18
- BMRN $9.99
- P/E Ratio
- CNA $13.76
- BMRN $20.29
- Revenue Growth
- CNA 6.34
- BMRN 19.36
- 52 Week Low
- CNA $44.09
- BMRN $52.93
- 52 Week High
- CNA $52.36
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- CNA 35.42
- BMRN 35.12
- Support Level
- CNA $44.62
- BMRN $54.46
- Resistance Level
- CNA $46.25
- BMRN $58.17
- Average True Range (ATR)
- CNA 0.82
- BMRN 1.39
- MACD
- CNA -0.16
- BMRN -0.04
- Stochastic Oscillator
- CNA 17.07
- BMRN 13.08
About CNA CNA Financial Corporation
CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.